Inhibitors of PD-1/PD-L1 are developing immunotherapy that can effectively block the PD-1/PD-L1 signalling pathway, ameliorate the tumor immune microenvironment, restore the anti-tumor activity of immune cells, and enhance endogenous anti-tumor activity. Here, CD274 is linked to neoplasm.